Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). IGC Pharma's share price for the quarter that ended in Dec. 2023 was €0.26. IGC Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 63.73 Mil. Therefore, IGC Pharma's market cap for the quarter that ended in Dec. 2023 was €16.57 Mil.
IGC Pharma's quarterly market cap
increased
from Jun. 2023 (€14.33 Mil) to Sep. 2023 (€19.62 Mil) but then
declined
from Sep. 2023 (€19.62 Mil) to Dec. 2023 (€16.57 Mil).
IGC Pharma's annual market cap
declined
from Mar. 2021 (€66.63 Mil) to Mar. 2022 (€44.98 Mil) and
declined
from Mar. 2022 (€44.98 Mil) to Mar. 2023 (€15.11 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. IGC Pharma's Enterprise Value for Today is €30.90 Mil.
IGC Pharma Market Cap Historical Data
The historical data trend for IGC Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IGC Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Market Cap falls into.
IGC Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
IGC Pharma's Market Cap for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (FRA:IGS1) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
IGC Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of IGC Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:IGS1 has been successfully added to your 